Gregory Maes: Representing Nonacus during General Assembly of the ELBS
Gregory Maes, Global Pharma and Strategic Alliances Manager at Nonacus, shared a post on LinkedIn:
” It was great to meet all ELBS members in beautiful and sunny Barcelona.
I really enjoyed representing Nonacus again during this year’s General Assembly of the European Liquid Biopsy Society (ELBS) in Barcelona.
A big thank you to Klaus Pantel for organizing this meeting and of course to Claudia Koch, PhD and Alina Brüns for compiling all presentations and social events together.
Our Nonacus team Chris Sale (Co-founder and CCO) and myself (Gregory Maes) had a fantastic time catching up with this dynamic Liquid Biopsy community, that are now becoming more friends than colleagues (see pictures).
As a precision medicine and liquid biopsy start-up, Nonacus focuses on precision and non-invasive healthcare technologies and has a mission to decentralise and democratise molecular testing for precision medicine and oncology.
I was delighted to present an update of our bladder cancer diagnostics and surveillance data from ongoing clinical studies, using our innovative GALEAS Bladder test. This test is not only already implemented by our UK partner Informed Genomics since end 2023 (reimbursed by Bupa already), but will soon get implemented on a European and global scale based on additional regional clinical studies.
We were also able to discuss in greater depth your interests and needs for innovative clinical solutions such as our high-precision NGS technology (for specific monitoring of patients in oncology, CDx, LBx or MRD, as well as other cfDNA pre-analytical solutions, perfectly suited to all liquid biopsy applications.
Developing a custom NGS panel has never been easier using our online panel design tool, which includes our enhanced library with the highest conversion rate on the market for multiple applications in precision oncology.
Finally, great insights were delivered during the satellite workshop on the regulatory opportunities and challenges of Liquid Biopsy in Europe.
Thanks to all presenters from GUIDE.MRD, The Synergist.org, Guardant Health and others.
If you would like to discuss more on bladder cancer testing, our innovative solutions and their implementation in your lab/diagnostics centre/company/drug development pipeline with CDx, please contact me (Gregory Maes) here or by email: [email protected].
For more information.
See you all next year again during upcoming Liquid Biopsy and MRD events.”
More posts featuring Gregory Maes.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023